Lutetium Lu 177 dotatate
Also known as: 177Lu-DOTATATE, 177Lu‑DOTA‑Tyr³‑Octreotate, 177Lu‑DOTATATE, Lu-177 DOTATATE, Lu‑177 dotatate, Lutathera, OPS201-Lu177, PRRT
Source Lutetium Lu 177 dotatate at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lutetium Lu 177 dotatate (Lutathera) is an FDA‑approved radiopharmaceutical that combines the somatostatin analogue DOTATATE with the beta‑emitting radionuclide lutetium‑177. It is indicated for patients with somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). By delivering targeted radiation to receptor‑expressing cells, it aims to control tumor growth while sparing most normal tissues.
Mechanism of Action
DOTATATE binds with high affinity to somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumor cells. The peptide‑chelator complex internalises, bringing the attached Lu‑177 isotope into the cell. Lu‑177 emits β‑particles (average energy ~0.5 MeV) that cause localized DNA damage, leading to tumor cell death, while its γ‑emission permits imaging. The chelator (DOTA) ensures in‑vivo stability, limiting systemic release of radioactivity.
What the Research Shows
Clinical use of Lu‑177‑DOTATATE for GEP‑NETs is established, as highlighted in recent regulatory reviews. Ongoing research expands its application to refractory meningioma, where semi‑automated 68Ga‑DOTATOC PET segmentation improves pre‑therapeutic dosimetry; SUVmean values correlate strongly with absorbed tumor dose (Pearson r up to 0.78). A review of resistance mechanisms notes that tumor heterogeneity, receptor down‑regulation, and prior therapies can diminish efficacy, prompting trials of combination strategies. Broad radiopharmaceutical trends underscore its role in theranostics, while regulatory analyses discuss formulation and supply challenges.
Reported Benefits
Approved Lu‑177‑DOTATATE delivers targeted β‑radiation to SSTR2‑positive tumors, achieving tumor control with reduced exposure to surrounding tissues compared with non‑targeted radiation. Dosimetry studies suggest that accurate PET‑based segmentation can predict absorbed dose, enabling personalized treatment planning and potentially enhancing therapeutic outcomes. Its dual imaging‑therapeutic capability supports treatment monitoring.
Limitations of the Evidence
Evidence of benefit beyond GEP‑NETs remains limited to small cohorts, such as refractory meningioma case series. Resistance can arise through receptor loss or prior therapies, as discussed in recent reviews, and may limit long‑term efficacy. Accurate tumor segmentation for dosimetry is technically demanding, and large‑scale, long‑term safety data are still emerging.
Safety Considerations
Lu‑177‑DOTATATE is a radiopharmaceutical, so radiation exposure to kidneys and bone marrow is a primary safety consideration. Published reviews note that the chelated complex limits off‑target radiation, but clinicians must monitor renal function and hematologic parameters. Detailed adverse‑event rates are not provided in the cited abstracts, underscoring the need for careful patient selection and follow‑up.
How It Is Administered
The agent is administered intravenously as a sterile solution of Lu‑177‑labeled DOTATATE. Dosing follows institutional protocols based on body surface area and renal function, with infusion typically lasting several minutes. Imaging can be performed using the γ‑emission for post‑therapy assessment.
Routes of Administration
Goals & Uses
- Treatment of somatostatin receptor-positive GEP-NETsOncology / Neuroendocrine Tumor ManagementHigh
- Symptom control in functional NETsSymptom ManagementModerate
- Symptom controlPalliativeModerate
- Treatment of GEP‑NETOncologyHigh
- Objective tumor response / tumor shrinkageOncology / Tumor ResponseModerate
- Treatment of other SSTR2-positive tumors (off-label/investigational)Oncology / Investigational UseLow
- Improvement of progression-free survival in NETsOncology / Disease ControlHigh
Contraindications
- Known hypersensitivity to peptide or DOTA chelateAllergyHigh
- Previous maximum radiation dose to critical organs (kidneys, bone marrow)Radiation OncologyHigh
- Severe renal impairment (eGFR <30 mL/min)RenalModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe renal impairment (eGFR <30 mL/min/1.73m²)RenalHigh
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
- Hypersensitivity to dotatate or Lu-177 componentsAllergy / ImmunologyHigh
Adverse Effects
- renal toxicityRenalUncommon
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- Myelosuppression (thrombocytopenia, anemia, lymphopenia)HematologicCommon
- Hepatotoxicity (elevated transaminases)HepaticUncommon
- Nausea/vomitingGastrointestinalCommon
- Nephrotoxicity / renal impairmentRenalUncommon
- Nausea and vomitingGastrointestinalCommon
- FatigueGeneralCommonLow energy or tiredness
- Radiation-induced myelodysplastic syndrome / acute leukemiaHematologic / Secondary MalignancyRare
- Hematologic toxicity (thrombocytopenia, neutropenia)HematologicCommon
Drug Interactions
- Myelosuppressive agents (chemotherapy, immunosuppressants)Moderate
- Long-acting somatostatin analogues (e.g., octreotide LAR)Moderate
- Aminoglycoside antibioticsModerate
- Nephrotoxic agents (e.g., aminoglycosides, NSAIDs, cisplatin)High
- Short-acting somatostatin analogues (e.g., octreotide SC)High
- Other radiopharmaceuticalsModerate
Population Constraints
- Patients with moderate renal impairment (eGFR 30-60 mL/min/1.73m²)RenalRelative
- Pediatric patientsAgeRelative
- Male patients with female partners of childbearing potentialReproductiveRelative
- Elderly with compromised marrow reserveAgeRelative
- Pregnant womenReproductiveAbsolute
- Patients with significant bone marrow involvement or prior myelotoxic therapyHematologicRelative
- Women of childbearing potentialReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: SSTR‑positive gastroenteropancreatic NETsEMA centralized procedure
- United StatesApprovedApproved: Somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumorsFDA label includes G1–G2 NETs
- United KingdomApprovedApproved: SSTR‑positive gastroenteropancreatic NETsMHRA approval
FDA approved (2018) for G1–G2 gastroenteropancreatic NETs; EMA approval 2017; UK MHRA approval 2018.
Evidence & Sources
- Journal ArticleModerate2018-01-01T00:00:00.000000Z
- Journal ArticleModerateBoursier C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateMcClellan K, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateMaithania H, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateBehera D, McEwan A2026-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of cancer are approved for treatment with Lu‑177‑DOTATATE?
Regulatory approvals list somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors as the primary indication. Research is exploring use in other SSTR‑expressing tumors, such as refractory meningioma, but these are not yet approved.
How does Lu‑177‑DOTATATE differ from conventional chemotherapy?
Unlike systemic chemotherapy, Lu‑177‑DOTATATE delivers beta radiation directly to cells that express somatostatin receptors, concentrating the cytotoxic effect while largely sparing non‑target tissues. It also provides built‑in imaging capability via its gamma emission.
What monitoring is required after treatment?
Patients are typically monitored for renal function, blood counts, and potential radiation‑related side effects. Imaging with gamma emissions can assess biodistribution and tumor uptake, guiding subsequent dosing decisions.
Can Lu‑177‑DOTATATE be combined with other therapies?
Reviews highlight ongoing trials investigating combinations with targeted agents, mTOR inhibitors, or other systemic treatments to overcome resistance, but definitive evidence for safety or efficacy of such combinations is still pending.
Is there a risk of radiation exposure to family members?
Because the radionuclide is bound within the peptide and excreted primarily via the kidneys, external radiation to others is minimal. Standard radiation safety guidelines recommend short‑term precautions, such as hydration and avoiding close contact with pregnant individuals for a brief period.
What is Lutetium Lu 177 dotatate?
Lutetium Lu 177 dotatate (Lutathera) is an FDA‑approved radiopharmaceutical that combines the somatostatin analogue DOTATATE with the beta‑emitting radionuclide lutetium‑177. It is indicated for patients with somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). By delivering targeted radiation to receptor‑expressing cells, it aims to control tumor growth while sparing most normal tissues.
What is Lutetium Lu 177 dotatate used for?
Lutetium Lu 177 dotatate is educationally associated with: Treatment of somatostatin receptor-positive GEP-NETs, Symptom control in functional NETs, Symptom control, Treatment of GEP‑NET, Objective tumor response / tumor shrinkage, Treatment of other SSTR2-positive tumors (off-label/investigational), Improvement of progression-free survival in NETs. Educational only — not medical advice.
How is Lutetium Lu 177 dotatate administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Lutetium Lu 177 dotatate?
Reported adverse effects include: renal toxicity, Hepatotoxicity, Myelosuppression (thrombocytopenia, anemia, lymphopenia), Hepatotoxicity (elevated transaminases), Nausea/vomiting, Nephrotoxicity / renal impairment, Nausea and vomiting, Fatigue, Radiation-induced myelodysplastic syndrome / acute leukemia, Hematologic toxicity (thrombocytopenia, neutropenia). This list is not exhaustive — consult a qualified clinician.
Who should avoid Lutetium Lu 177 dotatate?
Recorded contraindications: Known hypersensitivity to peptide or DOTA chelate, Previous maximum radiation dose to critical organs (kidneys, bone marrow), Severe renal impairment (eGFR <30 mL/min), Pregnancy, Severe renal impairment (eGFR <30 mL/min/1.73m²), Breastfeeding, Hypersensitivity to dotatate or Lu-177 components. Consult a qualified clinician before use.